Objectives: The objective of this study is to determine the rate of overall long-term sac regression following endovascular aneurysm repair (EVAR) and the influence of specific endograft devices used at our center.
Methods: This retrospective cohort study included all EVARs performed for intact and ruptured abdominal aortic aneurysms (AAAs) at a tertiary care, university teaching hospital. Preoperative, operative, and follow-up data were collected using a regional registry and institutional databases. Preoperative and post-EVAR sac diameters were determined by a blinded observer in accordance with Society for Vascular Surgery guidelines. Absolute and relative sac regression was determined at the intervals of 0 to 6 months, 6 to 12 months, 12 to 18 months, 18 months to 2 years, 2 to 5 years, 5 to 10 years, and >10 years.
Results: From 1999 to 2015, 1060 patients underwent EVAR for an AAA at the Ottawa Hospital, using nine unique endograft devices, with five devices (Cook Zenith, n ¼ 398; Medtronic Endurant, n ¼ 375; Medtronic Talent, n ¼ 183; Cook Zenith LP, n ¼ 52; and Terumo Anaconda, n ¼ 23) used in 97% of procedures. The mean preoperative AAA diameter was 61.2 mm, with no detectable differences between endograft devices with respect to age, preoperative AAA diameter, or rupture diagnosis. Overall mean sac regression went from e1.3 mm at 6 months to e14.9 mm >10 years. The majority of sac regression (88.7%) was achieved within 2 years. Only 90 of 1060 patients (8.5%) experienced sac expansion >5 mm at some point during their follow-up period. Kaplan-Meier analysis revealed that Zenith, Zenith LP, and Endurant endografts demonstrated the shortest time to >5 mm sac regression among devices used in >10 patients (Fig 1) . In patients who never had a type I endoleak in follow-up, the Zenith endograft demonstrated the most statistically significant sac regression at all intervals (Fig 2) . Cox proportional hazard modeling demonstrated that age <75 years (hazard ratio [HR], 1.4; P ¼ .001), female gender (HR, 1.4; P ¼ .003), absence of type I endoleak (HR, 4.6; P < .0001), AAA >70 mm (HR, 3.7; P < .0001) and that the Zenith (HR, 2.0; P < .0001) and Endurant (HR, 1.7; P ¼ .001) devices were both associated with shorter time to >5 mm sac regression.
Conclusions: This study demonstrated a pattern of sac diameter change following EVAR, with the majority of sac regression occurring within the first 2 years. Variability in sac regression was most influenced by age, gender, original AAA diameter, absence of endoleak, and endograft device. The relationship between specific endograft design and material, and sac regression is yet to be determined.
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Objectives: Literature has shown that a considerable percentage of endovascular aneurysm repair (EVAR) for abdominal aortic aneurysms (AAAs) has been performed outside the instructions for use (IFU). However, off-label EVAR durability and long-term patients' safety are still under investigations. We report long-term outcomes after EVAR with respect to a procedure performed according or not to the devices IFU. Sac regression in patients who had no evidence of any type I endoleak at any point during their follow-up. Statistically significant differences using analysis of variance and Tukey adjustment for multiple comparisons were detected for sac regression by endograft device in the setting of no type I endoleak (Zenith vs Talent endografts at 12 months, P < .012; at 18 months, P ¼ .004; 2 years, P < .0001, P ¼ .0007; 5 years, P ¼ .0004). A further difference was detected between Zenith and Endurant endografts at 5 years, P ¼ .0007. The dashed lines represent endografts placed in <10 patients and thus not included in statistical comparisons.
